The study addresses a long-standing unmet need for wearable technology to facilitate the accurate diagnosis of high blood pressure and early detection of preeclampsia, a leading cause of complications and mortality during pregnancy. “ViTrack technology offers a new and unprecedented ability to continuously measure blood pressure and other critical heart and respiratory data, to enable predictive monitoring for early diagnosis and management of preeclampsia, and to prevent prenatal and postpartum complications,” said Kecia Gaither, MD, Director of Perinatal Services and Maternal-Fetal Medicine at NYC Health + Hospitals/Lincoln.
Click HERE for the full press release.
